NFE2L2 expression in pancreatic and colorectal carcinoma cell lines was comprised between 29%–58% with respect to the observed in Hs766T (Figure 10B), thus the average percentage of expression in patients is significantly lower than the observed in sensitive cell lines. Here, NFE2L2 is linked to colorectal carcinoma.